Florbetaben F 18

(Neuraceq®)

Florbetaben F 18

Drug updated on 11/10/2023

Dosage FormInjection (intravenous: 50 to 5000 MBq/mL (1.4 to135 mCi/mL))
Drug ClassRadioactive diagnostic agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For positron emission tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.

Product Monograph / Prescribing Information

Document TitleYearSource
Neuraceq (florbetaben F 18) Prescribing Information.2022Life Molecular Imaging Ltd., Warwick, United Kingdom

Systematic Reviews / Meta-Analyses